Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Melanoma 1Lethal Congenital Contracture Syndrome 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Oxaliplatin 66pembrolizumab 48Fluorouracil 44Capecitabine 39Nivolumab 33Leucovorin 32Paclitaxel 28Trastuzumab 21Docetaxel 19Cisplatin 18S 1 (combination) 17Bevacizumab 15Drug Therapy 14Ramucirumab 13Irinotecan 13tislelizumab 12Cyclophosphamide 12fludarabine 10Carboplatin 10sintilimab 9Radiotherapy 9Magnetic Resonance Spectroscopy 9trastuzumab deruxtecan 8atezolizumab 8Specimen Handling 8Biopsy 8durvalumab 7Surgical Procedures, Operative 7Gemcitabine 7zolbetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × Paroxetine × 1 year × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡